 NEW YORK and LONDON, Sept. 07, 2021 GLOBE NEWSWIRE -- Tiziana Life Sciences plc NASDAQ: TLSA, LSE: TILS Tiziana or the Company, a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, will host a conference call and audio webcast on Wednesday, September 8, at 4:15 p.m. ET to discuss its recently announced exclusive license agreement to evaluate Foralumab, the Companys novel, fully human anti-CD3 monoclonal antibody, in conjunction with allogenic CAR T candidates for cancer treatment. 